Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TMR + CABG Trial Data Reveal Little About Procedure’s Efficacy – MCAC

This article was originally published in The Gray Sheet

Executive Summary

CMS should work with other HHS agencies to develop a new randomized trial comparing TMR + CABG to bypass alone, according to the Medicare Coverage Advisory Committee
Advertisement

Related Content

Renal Denervation Researcher Argues Sham Control Is Ethically Necessary
TMR + CABG Coverage To Continue, CMS Informs Thoracic Surgeons Society
TMR + CABG Coverage To Continue, CMS Informs Thoracic Surgeons Society
Percutaneous Myocardial Laser Developer Drafts IDE Agreement With FDA
Percutaneous Myocardial Laser Developer Drafts IDE Agreement With FDA
CMS Praises TMR Meeting, Plans To Convene MCAC More Often
CMS Praises TMR Meeting, Plans To Convene MCAC More Often
PET Trial For Alzheimer’s Opens Door For CMS-Backed Research – Phurrough
PET Trial For Alzheimer’s Opens Door For CMS-Backed Research – Phurrough
Advertisement
UsernamePublicRestriction

Register

MT020600

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel